Biotech News
Related news
NTLAIntellia2026-09-08 12:00 EST
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
NTLAIntellia2026-11-03 13:00 EST
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
RCKTRocket Pharmaceuticals2026-08-03 11:00 EST
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
CRSPCRISPR Therapeutics2026-11-04 14:01 EST
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
CRSPCRISPR Therapeutics2026-10-08 12:30 EST
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
OCGNOcugen2026-09-01 11:02 EST
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
RHHBYRoche Holdings AG2026-10-21 12:00 EST
Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026
GSKGSK plc2026-07-28 12:00 EST
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
GSKGSK plc2026-07-28 11:00 EST
GSK’s licensor Hansoh Pharma announces positive results from a second phase III trial for Ris-Rez in China
PHARPharming Group2026-09-22 05:00 EST
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
Intellia
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...
Recent company news
NTLAIntellia2026-11-06 21:05 EST
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLAIntellia2026-11-05 13:00 EST
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
NTLAIntellia2026-11-04 13:00 EST
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)
NTLAIntellia2026-11-03 13:00 EST
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
NTLAIntellia2026-10-29 12:00 EST
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026
Stock data
- Close
- 11.10 USD
- Market cap
- 1.83B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States